Structure Therapeutics Inc. (GPCR) stock
GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.17−0.40 (-2.15%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Structure Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Structure Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $294.24M, up 79.8% year over year. For fiscal 2025 it was $225.26M, up 107.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.26M | +107.0% |
| FY2024 | Dec 31, 2024 | $108.81M | +55.2% |
| FY2023 | Dec 31, 2023 | $70.10M | +93.7% |
| FY2022 | Dec 31, 2022 | $36.19M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $100.06M | +82.9% |
| Q1 FY2026 | Mar 31, 2026 | $66.51M | +55.1% |
| Q4 FY2025 | Dec 31, 2025 | $68.69M | +105.1% |
| Q3 FY2025 | Sep 30, 2025 | $58.99M | +81.0% |
| Q2 FY2025 | Jun 30, 2025 | $54.71M | +148.1% |
| Q1 FY2025 | Mar 31, 2025 | $42.87M | +107.3% |
| Q4 FY2024 | Dec 31, 2024 | $33.49M | +67.1% |
| Q3 FY2024 | Sep 30, 2024 | $32.60M | +86.1% |
| Q2 FY2024 | Jun 30, 2024 | $22.05M | +13.6% |
| Q1 FY2024 | Mar 31, 2024 | $20.68M | +57.4% |
| Q4 FY2023 | Dec 31, 2023 | $20.04M | +139.7% |
| Q3 FY2023 | Sep 30, 2023 | $17.52M | +91.2% |
| Q2 FY2023 | Jun 30, 2023 | $19.41M | +90.7% |
| Q1 FY2023 | Mar 31, 2023 | $13.14M | +54.7% |
| Q4 FY2022 | Dec 31, 2022 | $8.36M | – |
| Q3 FY2022 | Sep 30, 2022 | $9.16M | – |
| Q2 FY2022 | Jun 30, 2022 | $10.18M | – |
| Q1 FY2022 | Mar 31, 2022 | $8.49M | – |
See a number that looks wrong?